The Pill That Might Actually Slow Huntington's Disease

How This Drug Actually Works

Most failed Huntington's drugs have been injected directly into the spinal fluid. SKY-0515 is a daily pill. That alone makes it unusual.

The drug works by messing with RNA splicing, the cellular editing process that turns raw genetic instructions into finished protein blueprints. Normally, cells snip out certain segments (called introns) before assembling the final messenger RNA. SKY-0515 forces cells to keep one of those segments, intron 49, in the huntingtin gene transcript. That retained segment contains a stop signal, like a typo that causes the cell's quality-control system to shred the whole message before it ever becomes protein.

The result: less huntingtin protein gets made. At the higher dose, Skyhawk reported more than 60% reductions in mutant huntingtin levels, a strong biomarker signal that the drug is doing what it's supposed to do at the molecular level.

The company also reported reductions in PMS1, a mismatch-repair protein thought to drive the progressive expansion of the genetic stutter (CAG repeats) that causes Huntington's in the first place. Hitting both targets with one pill is like killing two birds with one very precisely thrown stone.

The Catch (Because There's Always a Catch)

Before anyone pops champagne, some important caveats.

This was a Phase 1/2 study, not a definitive Phase 3 trial. The comparison group wasn't a randomized placebo arm sitting in the same clinic; it was drawn from external natural-history databases, primarily Enroll-HD. That's a common approach in rare diseases where placebo-controlled trials are ethically and logistically tough, but it introduces uncertainty. Patients in a clinical trial tend to be different from patients in a registry, and those differences can skew results.

The drug also lowers both mutant and normal huntingtin protein. Whether long-term reduction of normal huntingtin causes problems remains an open question. Skyhawk reported no serious adverse events over 15 months, which is encouraging, but the study was small and the clock is still ticking.

Why This Matters Beyond One Drug

Huntington's disease affects roughly 30,000 people in the U.S., with another 200,000 or more at genetic risk. The therapeutic landscape in 2026 is busy: a systematic review found 21 agents currently being evaluated in registered studies, and disease-modifying candidates now make up over 90% of Phase 1 programs in the field.

But activity doesn't equal progress. The tominersen saga taught the field a painful lesson: lowering the bad protein isn't enough if clinical outcomes don't budge. SKY-0515's data are notable precisely because the clinical scores moved in the right direction, not just the biomarkers. That combination of mechanistic and functional evidence is what makes researchers cautiously optimistic rather than just politely interested.

Skyhawk isn't working in isolation, either. UniQure's gene therapy AMT-130 showed encouraging Phase 1/2 results and is pushing toward regulatory submission. A global Phase 3 trial called INVEST-HD began enrolling in early 2026, aiming to recruit about 770 patients across 30-plus countries. The Huntington's pipeline hasn't been this active in years.

What Comes Next

Skyhawk is advancing SKY-0515 into a pivotal study called FALCON-HD. That trial will need to replicate these results with a more rigorous design, likely including a randomized placebo control, to satisfy regulators.

The company is well-funded for the fight. Skyhawk has pulled in over $525 million in partnership payments from a roster that reads like a pharma all-star team: Bristol Myers Squibb, Biogen, Merck, Sanofi, Genentech, Vertex, and others. A $133 million funding round in 2021 added fuel.

Beyond Huntington's, Skyhawk's RNA-splicing platform has programs in spinocerebellar ataxia (SKY-1300) and frontotemporal dementia (SKY-1500), suggesting the technology could have legs well beyond a single disease.

For now, though, all eyes are on FALCON-HD. Fifteen months of promising data is a spark. The pivotal trial will determine whether it becomes a fire. After years of heartbreak, the Huntington's community is watching closely; this time, cautious hope might actually be warranted.

AstraZeneca's Breast Cancer Pill Had One Job. It Didn't Deliver.

AstraZeneca's oral breast cancer pill camizestrant missed its primary endpoint in the pivotal SERENA-4 trial, failing to prove a statistically significant benefit in first-line advanced breast cancer. The setback narrows the drug's commercial ceiling just as Eli Lilly's competing therapy racks up its second FDA approval.